A Randomized, Double Blind Multicenter Phase 3 Study of the Efficacy, Safety, and Tolerability of 28 Weeks of Brincidofovir vs Valganciclovir for the Precention of Cytomegalovirus Disease in High Risk Kidney Allograft Recipients (303)

Grants and Contracts Details

StatusFinished
Effective start/end date7/25/169/6/16

Funding

  • Chimerix Incorporated: $6,052.00